Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Daunorubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 0.99 |
| ▸ | MEN1 | O00255 | 10/20 | 1.00 |
| ▸ | THRB | P10828 | 10/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 10/20 | 1.00 |
| ▸ | BLM | P54132 | 9/20 | 1.00 |
| ▸ | RECQL | P46063 | 8/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | USP2 | O75604 | 5/20 | 1.00 |
| ▸ | S100A4 | P26447 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 1.00 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Daunorubicin SCHEMBL31326687 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL142541 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL31725676 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL4445 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL122984 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL4659664 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL20185623 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL2217102 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL20204237 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL29462666 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 27345 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| EP-3856736-B1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-3969123-B1 | LYMPHOTOXIN ALPHA FOR USE IN THERAPY OF MYELOID LEUKEMIA | CYCURIA THERAPEUTICS GMBH (AT) | 2026-04-29 | — | — | EP | claimed |
| US-20260109699-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2026-04-23 | — | — | US | claimed |
| EP-4727933-A1 | COMBINATION THERAPY METHODS FOR TREATING TP53-Y220C MUTANT AND TP53 WILDTYPE LEUKEMIAS | Board of Regents, The University of Texas System (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260102373-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2026-04-16 | — | — | US | claimed |
| US-20260096569-A1 | EDIBLE COATING WITH ANTIMICROBIAL PROPERTIES | APEEL TECH INC (US) | 2026-04-09 | — | — | US | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-20260069700-A1 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-12 | — | — | US | claimed |
| EP-0580171-A2 | Pharmaceutical composition containing a carrier bound antitumor substance | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1994-01-26 | — | — | EP | claimed |
| EP-0525073-A1 | ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA. | DU PONT (US) | 1993-02-03 | — | — | EP | claimed |
| EP-0088695-B1 | ANTIBODY CONJUGATES | CYTOGEN CORPORATION (US) | 1992-06-03 | — | — | EP | claimed |
| EP-0306541-B1 | PROCESS FOR OBTAINING DAUNORUBICIN-HYDROCHLORIDE FROM FERMENTATION BROTHS | BIOGAL GYOGYSZERGYAR (HU) | 1992-01-08 | — | — | EP | claimed |
| WO-1991015954-A1 | ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-10-31 | — | — | WO | claimed |
| US-5061492-A | biodegeadeable polymer matrix is copolymer of gylcolic acid a nd lactic acid | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-10-29 | — | — | US | claimed |
| US-4925662-A | ANTITUMOR AGENT BONDED TO HUMAN IMMUNOGLOBULIN | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1990-05-15 | — | — | US | claimed |
| US-4711782-A | Prolonged release microcapsules and their production | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-12-08 | — | — | US | claimed |
| US-4671958-A | Antibody conjugates for the delivery of compounds to target sites | CYTOGEN CORPORATION (US) | 1987-06-09 | — | — | US | claimed |
| EP-0122132-A2 | Anti-tumour substance | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1984-10-17 | — | — | EP | claimed |